Please assess the completion status of the following clinical trial:

Trial Title: Acipimox to Improve Hyperlipidemia and Insulin Sensitivity Associated With HIV

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Documented HIV infection~* Stable antiretroviral regimen for greater than 3 months~* Hypertriglyceridemia (fasting triglycerides greater than 150mg/dl)~* Evidence of fat redistribution (e.g., increased abdominal or cervical fat, and/or decreased subcutaneous fat of the face, arms, or legs) on physical exam~Exclusion Criteria:~* Current therapy with a lipid lowering medication (e.g., fibrates, HMG CoA reductase inhibitors, resins) or treatment with these agents in the 3 months prior to study entry~* Current use of hormone replacement therapy, oral contraceptives for women, or supraphysiologic testosterone therapy in men~* Fasting triglycerides greater than 1000mg/dl~* Active alcohol or substance abuse~* Active peptic ulcer disease~* History of renal failure or serum creatinine greater than 2.0~* Serious opportunistic infection within the 3 months prior to study entry~* Hemoglobin less than 11.0 mg/dl~* Elevated transaminase levels (AST or ALT greater than 2.5x the upper limit of normal)~* Previously diagnosed diabetes mellitus or patients receiving current treatment for diabetes

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).